Molecular Formula Of Inclisiran Sodium (Leqvio 01)
Leqvio Injection, Solution
Product Images NDC 0078-1000
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Leqvio (NDC 0078-1000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 1) (Leqvio 02)
This appears to be a table showing the percent change from baseline in patients taking either "incisarian" or a placebo for the "ORION-10" study. The study appears to involve 70-75 patients taking the placebo and 61-78 patients taking the incisiran over a period of several months.*
Figure 2: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Ascvd On Maximally Tolerated Statin Therapy (study 2) (Leqvio 03)
This appears to be a chart or table showing the levels of DL cholesterol in a group of patients who were either given a placebo or the drug "Inciiran." The number of patients in each group is listed, along with their cholesterol levels. However, without more context it is difficult to provide a more detailed description or interpretation of the data.*
Figure 3: Mean Percent Change From Baseline In Ldl-c Over 18 Months In Patients With Hefh On Maximally Tolerated Statin Therapy (study 3) (Leqvio 04)
The text describes the change in LDL cholesterol levels in patients receiving a drug called inclisiran compared to a placebo over a period of time. The data is presented in a table showing the number of patients in each group.*
Principal Display Panel Leqvio® (inclisiran) Injection Contains One Single-dose Prefilled Syringe For Subcutaneous Use For Administration By A Healthcare Professional Only 284 mg/1.5 mL (189 mg/ml) Ndc 0078-1000-60 Sterile Solution Rx Only Novartis (Leqvio 05)
LEQVIO® (inclisiran) injection is used for subcutaneous administration and comes in a single-dose pre-filled syringe of 1.5 mL containing 284mg inclisiran. It may contain sodium hydroxide and/or phosphoric acid for pH adjustment. The recommended dosage should be referred to in the prescribing information. The storage guidelines are between 2°C and 8°C (36°F and 46°F), with excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. It should be discarded after single use. The product contains no preservatives or natural rubber latex. For further information, visit www.LEQVIO.com or call 1-858-669-6652. Note: quality not high.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
